Corey McCann, Pear Therapeutics CEO
March 31, 2022 01:23 PM EDT
Pharma

Pear Ther­a­peu­tics sets the stage for a fruit­ful 2022, fore­cast­ing a five-fold boost in rev­enue

Nicole DeFeudis

Editor

Not so bad for its first earn­ings re­port. In a quar­ter­ly call on Mon­day, Pear Ther­a­peu­tics CEO Corey Mc­Cann cel­e­brat­ed the com­pa­ny’s “strong fi­nan­cial re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times